Glioblastoma Multiforme
- Glioblastoma Multiforme (GBM), also known as glioblastoma, is a type of cancer which is aggressive and develops within the brain.
- It is considered as a rapidly-growing glioma, which is developed from star-shaped glial cells including oligodendrocytes and astrocytes that supports the nerve cells in the brain.
- GBM is also known as grade IV astrocytoma and is considered as the most invasive forms of the glial tumors. This is a fast-growing and aggressive form of cancer in the central nervous system and will spread to the nearby brain tissues.
- The symptoms include seizures, vomiting, constant headaches, blurred or double vision, difficulty in speaking and also have similar symptoms like stroke showing poor blood flow to the brain that results in cell death. Worsening symptoms of GBM leads to unconsciousness.
- Also, tuberous sclerosis, neurofibromatosis, Von-Hippel-Lindau disease, Turcot syndrome, and Li-Fraumeni syndrome are the genetic disorders that are caused by increasing incidences of gliomas. As there is no current treatment found to be available for GBM, the market growth is known to rise shortly.
- Giving high doses of steroid helps to reduce the symptoms of brain swelling. Supply of various types of steroids in the market has failed to increase the survival rate.
- The treatment options that do not increase the overall survival rate in the patients like surgical resection is followed by chemotherapy and radiotherapy, is another factor contributing towards the expected growth of the market.
- The pipeline of GBM is rich with a lot of therapeutic drugs and devices that are expected to receive FDA approval shortly for the clinical trials.
- Currently, the FDA approved drugs of GBM are temozolomide that includes Temodar, Temodal and Tomcat, bevacizumab that provides for Avastin and carmustine wafers are going to fuel the GBM market. Temozolomide is introduced by NICE as one of the options for newly diagnosed GBM treatment.
- Temozolomide accounts for the largest market share concerning the revenue due to the advantages offered by the drug that includes delayed progression without hampering the quality of life and less adverse effects of the molecule.
- Furthermore, methylated or alkylated DNA in the drugs structural anomalies provides a better therapeutic efficacy that will lead to the high preference of the drug among the other segments. On the other side, pipeline drugs under phase III trials including Rindopepimut (CDX-110) and DCVax are known to be the fast-growing segment over the forecast period as a result of observation of adverse events in adult patients with the use of the available drugs.
- Biologic products produce a unique opportunity for focal treatment of GBM that presents a compelling and feasible procedure for the GBM patients which will contribute to the growth of the GBM market in the next few years.
- The habits of increasing alcohol consumption, increasing incidence of seizure and changing lifestyle are some of the drivers for the GBM market growth.
- Furthermore, the fact showing that glioma stem cells will resist conventional treatments raises urgent need for the alternative treatment therapies for GBM thus drives the market.
- Increasing of R&D in fields of gene therapy and molecular biotechnology for the treatment of CNS disorders and cancer is known to fuel the market growth across the forecast period. However, higher expenditure involved in the research employing genomics-based research is considered an essential restraint for the market.
